Photo from ajaxtherapeutics.com
May 14, 2024, 15:32
Big Day for Ajax Therapeutics with 2 big announcements
Ajax Therapeutics shared on X/Twitter:
“Big Day for Ajax Therapeutics with 2 big announcements! Number 1: We have closed our series C which gives us the resources to take our lead molecule to the clinic!
Ajax Announcement #2. The IND for our lead molecule, AJ-101095, a potent selective type II JAK inhibitor, has been cleared by the FDA. Next stop->clinic. Let’s go!.”
Source: Ajax Therapeutics/X and Ajax Therapeutics/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 5, 2024, 13:57
Nov 5, 2024, 10:35